Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials

翻译尚未完成，当前显示原文。

Key PointsEli Lilly is the leader in the GLP-1 weight-loss space, with Novo Nordisk working hard to regain lost market share.

阅读完整 Veytics 简报

我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。